Evidence map›Paper›PMID 37745505›Full record

ArticlebioRxiv : the preprint server for biology2023

Interferon-α promotes neo-antigen formation and preferential HLA-B-restricted antigen presentation in pancreatic β-cells.

Alexia Carré, Zhicheng Zhou, Javier Perez-Hernandez, Fatoumata Samassa, Christiana Lekka, Anthony Manganaro, Masaya Oshima, Hanqing Liao, Robert Parker, Annalisa Nicastri and 18 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 8 institutions in 7 countries.

Alexia CarréUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Zhicheng ZhouUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Javier Perez-HernandezUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Fatoumata SamassaUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Christiana LekkaIslet Biology Group, Exeter Centre of Excellence in Diabetes Research, University of Exeter Medical School, Exeter, UK.
Anthony ManganaroDiabetes Center of Excellence, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Masaya OshimaUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Hanqing LiaoCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, UK.
Robert ParkerCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, UK.
Annalisa NicastriCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, UK.
Barbara BrandaoUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Maikel L ColliULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium.
Decio L EizirikULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium.
Marcus GöranssonDepartment of Health Technology, Technical University of Denmark, Copenhagen, Denmark.
Orlando Burgos MoralesUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Amanda AndersonBarbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
Laurie LandryBarbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
Farah KobaisiUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Raphael ScharfmannUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Lorella MarselliDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Piero MarchettiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Sylvaine YouUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Maki NakayamaBarbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
Sine R HadrupDepartment of Health Technology, Technical University of Denmark, Copenhagen, Denmark.
Sally C KentDiabetes Center of Excellence, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Sarah J RichardsonIslet Biology Group, Exeter Centre of Excellence in Diabetes Research, University of Exeter Medical School, Exeter, UK.
Nicola TernetteCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, UK.
Roberto MalloneUniversité Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Centre National de la Recherche Scientifique · FRUniversity of Oxford · GBUniversity of Colorado Denver · USTechnical University of Denmark · DKUniversité Libre de Bruxelles · BEUniversity of Exeter · GBUniversity of Massachusetts Chan Medical School · USUniversity of Pisa · IT

Funding

University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
The Integrated Stress Response in Human Islets During Early T1DU01DK127786 · NIDDK · UNIVERSITY OF CHICAGO · PI EVANS-MOLINA, CARMELLA, MIRMIRA, RAGHAVENDRA G · 2020 to 2025
$7.1M
Molecular Dissection of Insulin Targeting in Anti-Islet AutoimmunityR01DK099317 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI AARON W MICHELS, Maki Nakayama · 2013 to 2026
$5.3M
Humanized Mouse Avatars for T1DU01DK104218 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BREHM, MICHAEL ALLEN, GREINER, DALE LESLIE · 2019 to 2023
$4.5M
Implications of Changes in Islet Exosomal Cargo in Type 1 DiabetesR01DK133881 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI EVANS-MOLINA, CARMELLA, MIRMIRA, RAGHAVENDRA G · 2022 to 2025
$2.7M
iPLA2beta-mediated alternative splicing and -cell death in type 1 diabetesR01DK126444 · NIDDK · UNIVERSITY OF VIRGINIA · PI CHALFANT, CHARLES E., EIZIRIK, DECIO LAKS · 2021 to 2024
$2.0M
Human Islet-Infiltrating T Cell Biology: Reactivity, Structure, and FunctionUC4DK116284 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HARLAN, DAVID MARSHALL, KENT, SALLY CHOATE · 2017 to 2017
$2.0M
NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK099317NIDDK NIH HHS R01 DK126444NIDDK NIH HHS R01 DK133881NIDDK NIH HHS U01 DK104218NIDDK NIH HHS U01 DK127786NIDDK NIH HHS UC4 DK116284
6 · The paper itself

Abstract

Interferon (IFN)-α is the earliest cytokine signature observed in individuals at risk for type 1 diabetes (T1D), but its effect on the repertoire of HLA Class I (HLA-I)-bound peptides presented by pancreatic β-cells is unknown. Using immunopeptidomics, we characterized the peptide/HLA-I presentation in

Identifiers

PMID37745505
PMCPMC10516036
OpenAlexW4386811366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.